TUMOR DEVELOPMENT

肿瘤发展

基本信息

批准号：
8378384
负责人：
ROBERT GLEN OSHIMA
金额：
$ 12.01万
依托单位：
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-05-21 至 2015-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8378384
关键词：
Area Bexarotene Biology Cancer Center Cancer Center Support Grant Cell Cycle Regulation Cells Collaborations Colon Cutaneous Defect Development Developmental Process Diagnostic Neoplasm Staging Epigenetic Process FDA approved Faculty Funding Genetic Genetic Processes Grant Interest Group Joints Laboratories Lead Malignant Neoplasms Mammary gland Mentors Microsatellite Instability Modeling Mus Mutation Nuclear Receptors Pathway interactions Peer Review Pharmaceutical Chemistry Pharmaceutical Preparations Phenotype Population Postdoctoral Fellow Productivity Program Development Publications RNA Research Resources Retinoids Role Signal Transduction Stem cells T-Cell Lymphoma Tissues Tretinoin Tumor stage United States National Institutes of Health cancer genetics cancer therapy carcinogenesis chromatin modification cost graduate student meetings member mouse model multidisciplinary neoplastic cell notch protein novel programs stem cell biology tumor

项目摘要

The Tumor Development Program focuses on understanding the genetic, epigenetic and developmental processes that take place in tumor-initiating cells and tumor-susceptible tissues during tumor development. The Program was established in 2007 by combining the Oncodevelopmental Biology Program with the Cancer Genetics & Epigenetics Program. This merger logically combines expertise in developmental aspects of cancer with genetic and epigenetic mechanisms underiying cancer development. Drs. Robert Oshima and Manuel Perucho are co-Leaders of the Program, which consists of 14 full members and 2 adjunct members. The Program comprises three overarching themes, which benefit from highly interdisciplinary program membership, including expertise in genetic and epigenetic pathways, stem cell biology, mouse models of cancer and medicinal chemistry: 1- Genetic and epigenetic changes in cancer. Program members continue to lead the field of the "mutator phenotype" and carcinogenesis, with additional strengths in the areas of chromatin modifications, cell cycle regulation and checkpoint signaling, and RNA biology; 2- Stem cell biology, with focus of Notch and Wnt signaling, and mouse models of cancer, with focus on mammary gland and colon models. The Program is a resource for all CCSG Programs due to its expertise in mouse tumor models; and 3- Novel targets in cancer treatment, with focus on nuclear receptors and retinoic acids. Notably, members of the Program have developed a retinoid-like drug, Targretin¿, which is FDA-approved for the treatment cutaneous T cell lymphoma. Members of this collaborative and multidisciplinary Program interact at a number of levels, including monthly faculty meetings and through collaborative grants. Program funding is currently at $12.9MM in annual total costs ($7.0MM direct). Program members participate in two POIs (1 from NCI), three U54/U19 grants, and 15 additional collaborative peer-reviewed federal and state grants. Program members also have 17 NIH ROIs (7 from NCI). The Program's productivity is further reflected by 345 publications since last review, and by 58 Program publications in 2008, which represent 14% of intra- and 21% of inter-programmatic collaborations, respectively.

肿瘤发展计划的重点是理解遗传，表观遗传和发育在肿瘤发育过程中发生在肿瘤发射细胞和肿瘤敏感的时机中发生的过程。该计划于2007年建立，通过将核心发育生物学计划与癌症遗传学和表观遗传学计划。该合并从逻辑上结合了开发专家癌症的各个方面具有癌症发展的遗传和表观遗传机制。博士。罗伯特 Oshima和Manuel Perucho是该计划的共同领导者，该计划由14名成员和2个组成辅助成员。该计划包括三个总体主题，这些主题受益于高度跨学科计划的成员资格，包括遗传和表观遗传途径的专业知识，干细胞生物学，癌症和医学化学的小鼠模型：1-癌症的遗传和表观遗传变化。计划成员继续领导“突变表型”和致癌的领域染色质修饰，细胞周期调节和检查点信号传导和RNA区域的优势生物学; 2-干细胞生物学，具有Notch和Wnt信号的焦点以及癌症的小鼠模型，重点关于乳腺和结肠模型。该程序是所有CCSG程序的资源小鼠肿瘤模型的专业知识； 3-癌症治疗中的新目标，重点是核接收器和视黄酸。值得注意的是，该计划的成员已经开发了类似类维生素类药物的targretin？被FDA批准用于治疗皮肤T细胞淋巴瘤。该协作和多学科计划的成员在许多层面上进行互动，包括月份教师会议和通过协作赠款。计划资金目前年度为12.9毫米费用（直接$ 7.0mm）。计划成员参加两种POI（来自NCI的1个），三个U54/U19赠款，以及 15额外的协作同行评审的联邦和州赠款。计划成员也有17个NIH ROI（NCI的7个）。自上次审查以来，该计划的生产率进一步反映了由2008年的58个计划出版物，占程序间内的14％和21％合作分别。